Recombinant Human PDCD1 Protein，His

PDCD1, commonly known as Programmed Cell Death Protein 1 (PD-1), is an immune checkpoint receptor that plays a crucial role in regulating immune responses and maintaining self-tolerance. High expression levels of PD-1 are found on activated T cells, B cells, and myeloid cells, and its interaction with its ligands, PD-L1 and PD-L2, can lead to the inhibition of T cell activation and proliferation. This mechanism is significant in the context of cancer, as many tumors exploit the PD-1/PD-L1 pathway to evade immune surveillance, making PDCD1 a prominent target for cancer immunotherapy. The development of PDCD1 recombinant proteins has allowed researchers to investigate the structural and functional properties of PD-1, facilitating the discovery of novel inhibitors that can block this pathway. Various studies have demonstrated that engineered antibodies and fusion proteins targeting PD-1 can enhance anti-tumor immunity, leading to significant clinical benefits in cancer patients. Additionally, understanding the molecular basis of PD-1 signaling can provide insights into autoimmune diseases, where PD-1 dysfunction is often implicated. As a result, PDCD1 recombinant proteins serve as valuable tools in both basic research and therapeutic applications, driving advancements in the fields of immunology and oncology.